Abstract:Aim: CDK4/6 have critical roles in the early stage of the cell cycle. CDK2 acts later in the cell cycle and has a considerably broader range of protein substrates, some of which are essential for normal cell proliferation. Therefore, increasing the selectivity of cyclin-dependent kinase (CDK) inhibitors is critical. Methodology: In this study, we construct a versatile, specific CDK4 pharmacophore model that not only matches well with 8119 of the reported 9349 CDK4/6 inhibitors but also differentiates from the CDK2 pharmacophore. Results & Conclusion: we demonstrate the activity and selectivity determinants of CDK4/6 selective inhibitors based on the CDK4 pharmacophore model. Finally, we propose the future optimization strategy for CDK4/6 selective inhibitors, providing a theoretical basis for further research and development of CDK4/6 selective inhibitors. [GRAPHICS] . Graphical abstract According to our CDK4 feature model, four decisive factors (capability as a hydrogen bond donor and acceptor, hydrophobicity, electrostatic potential) are highly desirable for potent inhibitory activity and selectivity. At present, most CDK4/6 selective inhibitors have similar skeletons and branches. The structure-activity relationship revealed by the 3D quantitation structure-activity relationships pharmacophore study is illustrated in the following picture. The key hydrogen bond with the hinge region (Val96) is indispensable for activity, although it does not play a major role in selectivity. Along the dotted line, we can design a hetero atom-containing group to form a hydrogen bond interaction with the Lys35(CDK4) at the bottom of the binding site. Selectivity is not the effect of a particular residue, but a cumulative effect. A unique hydrogen bonding between the side chain of His95 and the CDK4 inhibitor could improve the selectivity. There is no steric hindrance (Thr102) at the entrance of the binding pocket of CDK4, and the branch A of the scaffold could be designed to be larger such that it is appropriately positively charged and extends to the 'top' of the binding site (Asp99) to improve selectivity.

Development and strategies of CDK4/6 inhibitors

Elucidating Binding Selectivity in Cyclin-Dependent Kinases (CDKs) 4, 6, and 9: Development of Highly Potent and Selective CDK4/9 Inhibitors

Molecular Principle of the Cyclin-Dependent Kinase Selectivity of 4-(Thiazol-5-yl)-2-(phenylamino) Pyrimidine-5-carbonitrile Derivatives Revealed by Molecular Modeling Studies.

Cyclin-dependent Kinase Inhibition and Its Intersection with Immunotherapy in Breast Cancer: More Than CDK4/6 Inhibition

The Inhibitors of CDK4/6 from a Library of Marine Compound Database: A Pharmacophore, ADMET, Molecular Docking and Molecular Dynamics Study

An Insight into the Inhibitory Selectivity of 4-(Pyrazol- 4-Yl)-pyrimidines to CDK4 over CDK2

Targeting Cyclin-Dependent Kinases: From Pocket Specificity to Drug Selectivity

Discovery of novel macrocyclic derivatives as potent and selective cyclin-dependent kinase 2 inhibitors

Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors

Effect of Substituents in Different Positions of Aminothiazole Hinge-Binding Scaffolds on Inhibitor–CDK2 Association Probed by Interaction Entropy Method

Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors

Cooperation of structural motifs controls drug selectivity in cyclin-dependent kinases: an advanced theoretical analysis

Novel structural features of CDK inhibition revealed by an ab initio computational method combined with dynamic simulations

Identification of Novel CDK 4/6 Inhibitors by High-throughput Virtual Screening

Exploring the Selectivity of Tetrahydropyrido[1,2-a]isoindolone Derivatives to GSK3 beta and CDK5 by Computational Methods

The novel selective inhibitors of cyclin-dependent kinase 4/6: in vitro and in silico study

Design, Synthesis, and Biological Evaluation of 2,4-Diaminopyrimidine Derivatives as Potent CDK7 Inhibitors

Identification of novel CDK 9 inhibitors based on virtual screening, molecular dynamics simulation, and biological evaluation

Imidazole-4-N-acetamide Derivatives as a Novel Scaffold for Selective Targeting of Cyclin Dependent Kinases

A Robust Computational Framework for the Optimization of CDK7 Inhibitors as Promising Cancer Therapy

Discovery and optimization of thieno[3,2- d ]pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7